Physician
Family Medicine
Dr. Matthew R. Lee is an expert in the field of Family Medicine. He went to medical school at University of Louisville School of Medicine. University of Louisville School of Medicine is ranked 83 in research and 0 in primary care medicine He has 1 awards "CMS Meaningful Use Stage 1 Certification". Doctor Matthew R. Lee, MD is also a published doctor. He has 34 publication published. The most recent publication is: Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors. He is registered with Medicare and accepts Medicare payments.
Publications
- Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
- The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
- The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.
- Maturing out of alcohol involvement: Transitions in latent drinking statuses from late adolescence to adulthood.
- Development and implementation of Baltimore Healthy Eating Zones: a youth-targeted intervention to improve the urban food environment.
- Does time heal all wounds? Community attachment, natural resource employment, and health impacts in the wake of the BP Deepwater Horizon disaster.
- Process evaluation of Healthy Bodies, Healthy Souls: a church-based health intervention program in Baltimore City.
- Quinolinone-based agonists of S1P(1): Use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
- Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
- Reconsidering the culture and violence connection: strategies of action in the rural South.
- The effect of marriage on young adult heavy drinking and its mediators: results from two methods of adjusting for selection into marriage.
- Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
- Community covariates of malnutrition based mortality among older adults.
- Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated prote...
- Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structu...
- Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
- Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
- 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
- Design, synthesis, and biological evaluation of potent c-Met inhibitors.
- Labor market conditions and violent crime across the metro-nonmetro divide.
- Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
- Frequency and intensity of social anxiety in Asian Americans and European Americans.
- Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases.
- Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated prot...
- MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.
- Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.
- 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
- Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated prot...
- Azole-based inhibitors of AKT/PKB for the treatment of cancer.
- Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.
- Protein kinase C isozymes as potential therapeutic targets in immune disorders.
- Identification of triazolopyridazinones as potent p38α inhibitors.
- Civic community and nonmetropolitan White suicide.
Schools
University of Louisville School of Medicine
Deaconess Hospital
Doctors Specialties
Accepted Insurances
- Choice Plus POS II
- American Enterprise Group
- American Republic
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Assurant Health
- AvMed
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Coventry Health Care of Illinois PPO
- Platinum PPO
- First Health (Coventry Health Care) PPO
- Health Alliance PPO
- HealthLink PPO
- Choice Care PPO
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Medico
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Pekin Insurance
- Principal Life
- Priority Health
- Sagamore Plus
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Worker's Compensation WC
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Louisville School of Medicine
Drug Facts
| NPI NUMBER |
|
1902842941 |
| NPPES Provider LastName |
|
LEE |
| NPPES Provider FirstName |
|
MATTHEW |
| NPPES Provider ZIPCode |
|
47620 |
| NPPES Provider State |
|
IN |
| Specialty Description |
|
Family Practice |
| Total Claim Count |
|
17766.0 |
| Distinct Opioid Count |
|
6.0 |
| Opioid Claim Count |
|
1746.0 |
| Percent Opioid Claims |
|
9.83 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1902842941 |
| Last Name Of The Provider |
LEE |
| First Name Of The Provider |
MATTHEW |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.